• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    九

    九州大学医院

    Kyushu University Hospital
    EST. 1867
    4,854论文总数
    8.4万引用总数

    论文量&引用量时间轴

    机构学者

    论文(4854)

    年份
    起
    –
    止
    排序
    1Long-term Trends and Regional Variation in Mortality from Ischemic Heart Disease in Korea and Japan, 1999–2023
    Minsung Cho,Eunji Kim,Kyoung Hwa Ha,Hokyou Lee,Tasuku Okui,Hyeon Chang Kim
    2027Korean Circulation Journal(2027)
    引用
    AI阅读
    加入学术空间
    2Five-year Interim Analysis of J-SKI: an Observational Study of TKI Discontinuation in Patients with CML in Japan
    Naoto Takahashi,Shinya Kimura,Eri Matsuki,Takaaki Ono,Noriko Doki,Masaki Iino,Masashi Sawa,Yoshio Saburi,Kazunori Murai,Katsumichi Fujimaki,Shingo Kurahashi,Noriyoshi Iriyama,

    Treatment-free remission (TFR) is an emerging goal for patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI). However, long-term TFR durability in real-world settings remains understudied. The J-SKI study, a large observational study, was conducted to evaluate long-term TFR outcomes in Japanese patients with CML. This interim analysis included 795 eligible patients from the prospective (n = 283) and retrospective (n = 512) cohorts. With a median follow-up of 32 months (range 0.8–168) after TKI discontinuation, the 5-year TFR rate was 65.2

    2026International Journal of Hematology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Systematic Review and Meta-Analysis for JCS 2026 Guideline on Management of Large-Vessel Vasculitis.
    Tsuyoshi Shirai, Tsuneyasu Yoshida, Eri Sugano,Ryosuke Hiwa, Ryuhei Ishihara,Ryo Yanai, Nobuyuki Yajima,Takashi Kida, Norihiro Nishioka,Ryota Sakai, Takaya Handa, Manabu Honda,

    BACKGROUND:To provide evidence from randomized controlled trials (RCTs) for large-vessel vasculitis (LVV), including Takayasu arteritis (TAK) and giant cell arteritis (GCA), to inform the forthcoming 2026 Japanese Circulation Society (JCS) clinical practice guideline. METHODS AND RESULTS:We drafted 4 and 7 clinical questions for TAK and GCA, respectively. A systematic review (SR) of RCTs was conducted using PubMed, CENTRAL, EMBASE, and the Japan Medical Abstracts Society through March 2024. Assessed with the GRADE approach, the certainty of evidence was very low for the most critical outcomes, low for some outcomes, and moderate for only 1 outcome. Evidence for TAK was limited. Tocilizumab (TCZ) resulted in a numerically lower relapse rate vs. placebo (risk ratio (RR) 0.73, 95% confidence interval (CI) 0.39-1.37) and was similar to adalimumab. No clear difference between mycophenolate mofetil (MMF) and methotrexate (MTX), or between abatacept (ABA) and placebo was observed. In GCA, TCZ reduced relapse (RR 0.29, 95% CI 0.09-0.98) and increased remission (RR 3.56, 95% CI 2.29-5.54) over placebo at 52 weeks. Tumor necrosis factor inhibitor, ABA, and MTX showed no benefit in cranial GCA. Serious adverse events were comparable between treatment groups. Geographic variation and differences in entry criteria were noted. CONCLUSIONS:This SR was comprehensive synthesis of evidence from RCTs for LVV therapies to support the 2026 JCS guideline.

    2026Circulation journal official journal of the Japanese Circulation Society(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
    Maurice Perol,Tatsuya Yoshida,Myung-Ju Ahn,Carl M. Gay,Martin Schuler, Haifeng Liu,Ahmet Sezer,Ahmet Bilici,Ippokratis Korantzis,Sun Min Lim,Kohei Otsubo,Oscar Juan-Vidal,

    Background Patients with extensive-stage small-cell lung cancer have poor outcomes, with a median overall survival of approximately 12 to 13 months. Tarlatamab (a bispecific T-cell engager targeting delta-like ligand 3 [DLL3] and CD3) was previously shown to improve survival as second-line therapy. Whether adding tarlatamab to durvalumab (an anti-programmed death ligand 1 agent) after initial chemoimmunotherapy could significantly improve survival in the context of maintenance therapy after first remission has been unclear. Methods In this phase 3, international, open-label, randomized trial, we compared tarlatamab-durvalumab with durvalumab as first-line maintenance therapy in patients with extensive-stage small-cell lung cancer without progression after initial chemoimmunotherapy. Overall survival and progression-free survival were assessed from randomization at the start of maintenance therapy as the primary and key secondary end points, respectively. Results of the prespecified interim analysis (data-cutoff date, July 7, 2026) are reported here. Results A total of 563 patients were randomly assigned to receive tarlatamab-durvalumab (282 patients) or durvalumab (281 patients). At a median follow-up of 15.9 months in the tarlatamab-durvalumab group and 16.1 months in the durvalumab group, the estimated median overall survival was 21.1 months (95% confidence interval [CI], 20.8 to could not be estimated) with tarlatamab-durvalumab and 12.7 months (95% CI, 11.2 to 14.8) with durvalumab (hazard ratio for death, 0.42; 95% CI, 0.32 to 0.54; P<0.001). The median progression-free survival was 7.4 months (95% CI, 5.6 to 9.1) with tarlatamab-durvalumab and 1.9 months (95% CI, 1.9 to 2.0) with durvalumab (hazard ratio for disease progression or death, 0.34; 95% CI, 0.28 to 0.42; P<0.001). Adverse events of grade 3 or higher occurred in 46.8% of the patients who received tarlatamab-durvalumab and in 40.6% of those who received durvalumab alone. Cytokine release syndrome, mainly of grade 1 or 2, was seen in nearly half the patients receiving tarlatamab-durvalumab. Conclusions Tarlatamab-durvalumab maintenance therapy resulted in significantly longer overall survival and progression-free survival than durvalumab alone among patients with extensive-stage small-cell lung cancer. (Funded by Amgen and AstraZeneca; DeLLphi-305 ClinicalTrials.gov number, NCT06211036.)

    2026NEW ENGLAND JOURNAL OF MEDICINE(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Drivers of Temporal Improvement in CAR T-cell Therapy for Large B-cell Lymphoma: a Japanese Nationwide Registry Analysis.
    Yu Yagi,Yusuke Kanemasa,Toshiki Terao,Motohiro Kato, Tomoyasu Jo,Tatsu Shimoyama,Toshio Kitawaki,Ryo Hanajiri,Noriko Doki,Satoshi Yoshihara,Nobuharu Fujii,Noriko Iwaki,

    ABSTRACT:Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed/refractory (R/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.

    2026Blood advances(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4854 篇论文

    合作机构(100)

    九州大学合作论文 2,332
    东京大学合作论文 168
    Hamanomachi Hospital合作论文 160
    京都大学合作论文 145
    National Kyushu Medical Center,National Hospital Organization合作论文 118
    福冈大学合作论文 116
    名古屋大学合作论文 102
    Hokkaido University Hospital合作论文 102
    近畿大学合作论文 96
    大阪大学合作论文 95

    机构统计